Sectors
UNCY
Unicycive Therapeutics, Inc.
5.20
2 x 3.80
2 x 6.64
bid
ask
-
0.06
1.23%
2 @ 06:57 PM
5.22 +0.02 (0.38%)
| Ytd | -9.88% | |
| 1y | 24.11% |
5.13
day range
5.25
3.71
52 week range
8.74
| Open | 5.24 | Prev Close | 5.26 | Low | 5.13 | High | 5.25 | Mkt Cap | 142.44M |
| Vol | 574.17K | Avg Vol | 1.51M | EPS | -1.75 | P/E | N/A | Forward P/E | -3.31 |
| Beta | 2.29 | Short Ratio | 0.74 | Inst. Own | 38.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 5.63 | 200-d Avg | 6.42 | 1yr Est | 5.50 |
| Income Statement | |||
| Operating Expenses | 10.14M | ||
| Research and Development Expense | 2.79M | ||
| Selling, General and Administrative Expense | 7.35M | ||
| Operating Income | -10.14M | ||
| Net Income | -1.72M | ||
| Net Income Common Stock | -1.72M | ||
| Net Income Common Stock (USD) | -1.72M | ||
| Consolidated Income | -1.72M | ||
| Earnings per Basic Share | -0.06 | ||
| Earnings per Basic Share (USD) | -0.06 | ||
| Earnings per Diluted Share | -0.06 | ||
| Earning Before Interest & Taxes (EBIT) | -1.72M | ||
| Earning Before Interest & Taxes (USD) | -1.72M | ||
| Weighted Average Shares | 26.92M | ||
| Weighted Average Shares Diluted | 26.92M | ||
| Balance Sheet | |||
| Cash and Equivalents | 44.19M | ||
| Cash and Equivalents (USD) | 44.19M | ||
| Investments | 17.24M | ||
| Investments Current | 17.24M | ||
| Current Assets | 71.32M | ||
| Property, Plant & Equipment Net | 709.00K | ||
| Total Assets | 72.03M | ||
| Debt Current | 616.00K | ||
| Total Debt | 671.00K | ||
| Current Liabilities | 18.70M | ||
| Debt Non-Current | 55.00K | ||
| Total Liabilities | 18.76M | ||
| Accumulated Retained Earnings (Deficit) | -142.37M | ||
| Accumulated Other Comprehensive Income | -23.00K | ||
| Shareholders Equity | 53.27M | ||
| Shareholders Equity (USD) | 53.27M | ||
| Assets Non-Current | 709.00K | ||
| Total Debt (USD) | 671.00K | ||
| Liabilities Non-Current | 55.00K | ||
| Trade and Non-Trade Payables | 2.23M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 151.00K | ||
| Net Cash Flow from Financing | 14.44M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 6.81M | ||
| Capital Expenditure | 1000 | ||
| Issuance (Purchase) of Equity Shares | 14.44M | ||
| Net Cash Flow from Investing | -23.00K | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -24.00K | ||
| Net Cash Flow from Operations | -7.60M | ||
| Share Based Compensation | 2.88M | ||